The Public Committee for the Expansion of the Drug Basket has selected 133 drugs and technologies to be given free of charge to patients, out of 850 submitted for approval.
As every year, there are patients for whom this is life-saving gospel and others who are disappointed.
Shmulik Ben Yaakov, chairman of the Association for Patient Rights, commented that the committee was supposed to submit its recommendations by the end of December but is a month late: "The basket committee makes important and fateful decisions for many patients in the health system A month means a difficult meeting in health. "
Ben Yaakov added: "The fact that we are talking about the decisions of the Basket Committee for 2022, towards the end of the first month of 2022, hurts tens of thousands of patients who had to wait another 4 weeks and therefore, it is important to determine the committee's working procedures." "In October, and submitting its recommendations by the end of December, and for that it is necessary for the committee members to be elected for a period of 4 years and not an annual appointment as is customary today."
Eliezer Ben Harush, 56, from Moshav Megadim, a patient with kidney failure, welcomes the approval of the drug Forsiga for him and other kidney failure patients.
"I am happy with the decision of the basket committee to include the drug Forsiga. This drug can prevent the deterioration of many patients and save the need for dialysis and kidney transplantation. This news is important for thousands of patients in Israel. "I can definitely beat the disease. I have no doubt that the future for kidney failure patients will be better."
Eliezer ben Harush.
Patient with kidney failure,
Eileen Bloch Levy, 70, Shaarei Tikva, has multiple myeloma. She and 60 other patients will be treated for the medication they need. "Hope always wins! I have had multiple myeloma since 2012, I have had 2 bone marrow transplants, and many medical treatments for my condition, each lasting between seven months and two years, I have undergone all possible treatments, my coronary heart disease prevents me from seeing my grandchildren and living life. .
Hadassah Bitton, 49, from Be'er Sheva, a type 2 diabetic, will receive funding for the sugar study she already uses today: "Today I and thousands of other type 2 diabetics can breathe a sigh of relief. I have been diabetic for about five years and over the years have suffered from diabetes. One year I discovered the Libra freestyle system that changed my life and thanks to it I manage to maintain balanced sugar levels. I monitor my sugar levels at least 8 times a day and thanks to that I manage to behave well alongside diabetes. I am happy that the basket committee included the important technology ".
Hadassah Bitton.
Diabetic patient.,
Patients left behind: "It means for me to continue to suffer from the disease"
Among the disappointed patients is Yuli Yagodin, 38, from Raanana, who has had myasthenia gravis for about six years and needs the drug Soliris: "I am very disappointed. For a long time I could not eat hard food, I ate only soft foods in small amounts, I lost weight, had difficulty dressing and showering alone, and could not function at home, my husband had to leave work as an employee and work as a freelancer. To take care of me and our two children who were still small, and also to accompany me for examination and treatments. "It costs about a million shekels a year! I will continue to fight so that this medicine enters the basket, and so that I can continue to live a good life."
July Godin.
A patient from Estonia Garbis,
Inbal Cohen Tuval, general manager of the Israel Skin Cancer Association, is disappointed that the drug Libtio for non-melanoma skin cancer patients did not enter the drug basket:
These are patients most of whom are very old, and do not always notice in time the lesions in their body until they become very severe wounds, causing great pain and dangers of infection.
These are wounds that the drugs currently in the basket fail to help and cure.
"The older patients, who have suffered enough in the last two years from social and family isolation and distance during the epidemic, are left behind this time as well."
David Atrezda, 60: "I have been suffering from atopic dermatitis in a severe condition for about 6 years. Normal, can not sleep or shower and also avoid encounters with people because of the appearance of my skin.Unfortunately the drug 'Rinbock' for the treatment of the disease, did not enter the drug basket this year, and the meaning for me and other patients in my condition is to continue suffering from the disease. "I am very disappointed with the decision of the basket committee and hope that the drug will enter the basket next year."
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us
